Quantitative proteomic analysis using a mouse model of Lewy body dementia induced by α-synuclein preformed fibrils injection

The aggregation of α-synuclein in the nervous system leads to a class of neurodegenerative disorders termed α-synucleinopathies. A form of primary degenerative dementia called Lewy body dementia (LBD) often develops when these aggregations develop into intracellular inclusions called Lewy bodies (LB) and Lewy neurites (LN). Although high frequency of LBD are the leading cause of dementia after Alzheimer's disease (AD), limited information has been discovered about its pathological pathway or diagnostic criteria. In this report, we attempt to address such shortcomings via utilizing a proteomic approach to identify the proteome changes following intrastriatal injection of α-synuclein pre-formed fibril (α-syn PFF). Using mass spectrometry, we have identified a total of 179 proteins that were either up- or down-regulated at different time points, with the four proteins-TPP3, RAB10, CAMK2A, and DYNLL1, displaying the most significant changes throughout the timeframe. Through further examining the modulated proteins with network-based enrichment analyses, we have found that (1) the most significantly associated neurodegenerative pathways were Parkinson's (<i>p</i>V = 3.0e-16) and Huntington's (<i>p</i>V = 1.9e-15) disease, and (2) the majority of molecular functions specific to the pathology only appeared at later time points. While these results do not expose a conclusive biomarker for LBD, they suggest a framework that is potentially applicable to diagnose and differentiate LBD pathology from other forms of dementia by focusing on the cortical proteome changes which occur in a later time span.

Authors

Institutions

Publication Details

Journal
Frontiers in Dementia
Published
2024-10-28
DOI
https://doi.org/10.3389/frdem.2024.1477986
Citations
2
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
0.74

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Quantitative proteomic analysis using a mouse model of Lewy body dementia induced by α-synuclein preformed fibrils injection

Sung-Ung Kang, Heejin Jo, Yoonseop Choi, In Kyu Jang et al.
2 citations
Frontiers in Dementia
Parkinson's Disease Mechanisms and Treatments
0.74
article

Quantitative proteomic analysis using a mouse model of Lewy body dementia induced by α-synuclein preformed fibrils injection

Sung-Ung Kang, Heejin Jo, Yoonseop Choi, In Kyu Jang, Chan Hyun Na, Fatih Akkentli, Lois G. Kim, Jinhee Park, Jinchong Xu, Aashi Mendpara, Bikram Bains, Dongyoon Yoo
article en
2 citations

Abstract

The aggregation of α-synuclein in the nervous system leads to a class of neurodegenerative disorders termed α-synucleinopathies. A form of primary degenerative dementia called Lewy body dementia (LBD) often develops when these aggregations develop into intracellular inclusions called Lewy bodies (LB) and Lewy neurites (LN). Although high frequency of LBD are the leading cause of dementia after Alzheimer's disease (AD), limited information has been discovered about its pathological pathway or diagnostic criteria. In this report, we attempt to address such shortcomings via utilizing a proteomic approach to identify the proteome changes following intrastriatal injection of α-synuclein pre-formed fibril (α-syn PFF). Using mass spectrometry, we have identified a total of 179 proteins that were either up- or down-regulated at different time points, with the four proteins-TPP3, RAB10, CAMK2A, and DYNLL1, displaying the most significant changes throughout the timeframe. Through further examining the modulated proteins with network-based enrichment analyses, we have found that (1) the most significantly associated neurodegenerative pathways were Parkinson's (<i>p</i>V = 3.0e-16) and Huntington's (<i>p</i>V = 1.9e-15) disease, and (2) the majority of molecular functions specific to the pathology only appeared at later time points. While these results do not expose a conclusive biomarker for LBD, they suggest a framework that is potentially applicable to diagnose and differentiate LBD pathology from other forms of dementia by focusing on the cortical proteome changes which occur in a later time span.

Frontiers in DementiaVol. 3
Johns Hopkins University (US), Johns Hopkins Medicine (US)
National Institutes of Health, National Institute of Neurological Disorders and Stroke
Good health and well-being
Openalex Percentile: Top 26%
Parkinson's Disease Mechanisms and Treatments
0.74
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.